Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors

Authors

Diana Merino Vega, Friends of Cancer Research
Aadel A Chaudhuri, Washington University School of Medicine in St. Louis
et al

Journal

JCO Precision Oncology

Publication Date

8-1-2022

Volume

6

First Page

e2100372

Document Type

Open Access Publication

DOI

10.1200/PO.21.00372

Rights and Permissions

Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, Rosenthal A, Anagnostou V, Baden J, Beaver JA, Chaudhuri AA, Chudova D, Fine AD, Fiore J, Hodge R, Hodgson D, Hunkapiller N, Klass DM, Kobie J, Peña C, Pennello G, Peterman N, Philip R, Quinn KJ, Raben D, Rosner GL, Sausen M, Tezcan A, Xia Q, Yi J, Young AG, Stewart MD, Carpenter EL, Aggarwal C, Allen J. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. JCO Precis Oncol. 2022 Aug;6:e2100372. doi: 10.1200/PO.21.00372 Creative Commons Attribution Non-Commercial No Derivatives 4.0 License http://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Vega, Diana Merino; Chaudhuri, Aadel A; and et al, "Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors." JCO Precision Oncology. 6, e2100372 (2022).
https://digitalcommons.wustl.edu/oa_4/325